Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

March 10, 2021

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

February 24, 2021

Jonathan C. Trent, MD, PhD, discusses the need to develop novel combination strategies for the treatment of patients with metastatic gastrointestinal stromal tumors.

February 18, 2021

In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.

February 10, 2021

Aditi Dhir, MD, discusses risk-based stratification in patients with epithelioid and synovial sarcoma.

February 05, 2021

Aditi Dhir, MD, discusses the challenges of diagnosing patients with sarcoma.

January 06, 2021

Aditi Dhir, MD, discusses modifying treatment for adults versus pediatric patients with epithelioid sarcoma.

January 04, 2021

Faculty of a recent Institutional Perspectives in Cancer webinar on sarcoma, hosted by Sylvester Comprehensive Cancer Center, share updates in the management of gastrointestinal stromal tumor, epithelioid and synovial sarcoma, and tenosynovial giant cell tumor.

November 19, 2020

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

November 05, 2020

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

November 02, 2020

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men. 

October 30, 2020

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

October 23, 2020

Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.

October 21, 2020

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

October 09, 2020

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.

September 02, 2020

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

August 19, 2020

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

August 07, 2020

Jonathan C. Trent, MD, PhD, discusses the role of circulating tumor DNA in soft tissue sarcoma. 

May 27, 2020

Gilberto de Lima Lopes, MD, discusses the appropriate duration of immunotherapy in lung cancer, treatment-related adverse events, and remaining challenges faced in the space.

May 21, 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

May 20, 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.